Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.56 |
| ▸ | THRB | P10828 | 7/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282142 | 0.86 | RORC (0.46) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL6694659 | 0.84 | RORC (0.49) | RORCTHRBTHRA | |
| SCHEMBL6692303 | 0.83 | RORC (0.48) | RORCTHRBTHRA | |
| SCHEMBL6689993 | 0.83 | RORC (0.48) | RORCTHRBTHRA | |
| SCHEMBL6691984 | 0.83 | RORC (0.48) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL6692393 | 0.82 | THRB (0.39) | RORCTHRB | |
| SCHEMBL6694189 | 0.81 | TUBB1 (0.54) | RORCTHRB | |
| SCHEMBL7258641 | 0.80 | RORC (0.49) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL6694977 | 0.77 | L3MBTL1 (0.42) | — | |
| SCHEMBL6693303 | 0.77 | TUBB1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003094845-A2 | PYRIDINE-BASED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | RORC 173/4885THRB 2/4885P2RX3 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.